Literature DB >> 8640983

Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.

T Ogawa1, W Linz, M Stevenson, B G Bruneau, M L Kuroski de Bold, J H Chen, H Eid, B A Schölkens, A J de Bold.   

Abstract

BACKGROUND: In hypertension with cardiac hypertrophy, the specific contributions to increased production of the cardiac natriuretic peptides (NP) atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) by load and the hypertrophic process are not known. In the present work we determine ANF and BNP synthesis and secretion in the aortic-banded rat treated with dosage schedules of the ACE inhibitor ramipril that result in the prevention or regression of both hypertension and hypertrophy (high dosage) or in the prevention or regression of hypertrophy alone with persistent hypertension (low dosage). Myosin heavy chain (MHC) isoform switch was studied as an indicator of ventricular cardiocyte hypertrophy as well as the levels of collagen III mRNA as a measure of changes in extracellular matrix. METHODS AND
RESULTS: Ramipril was administered for 6 weeks just after suprarenal aortic banding, or rats were banded for 6 weeks, after which ramipril was administered during the following 6 weeks. Banding caused an increase in blood pressure, left ventricular weight-to-body weight ratio, plasma and ventricular NP, ventricular NP mRNA, collagen III, and beta-MHC mRNA. Ramipril at 1 mg/kg normalized all these parameters while ramipril at 10 micrograms/kg normalized left ventricular weight-to-body weight ratio but not blood pressure. Plasma and ventricular NP content and mRNA levels were partially normalized by ramipril (10 micrograms/kg). Ramipril (10 micrograms/kg) prevented increased collagen III mRNA levels but did not affect beta-MHC mRNA levels.
CONCLUSIONS: (1) NP production and secretion in aortic-banded rats are independently related to increased blood pressure and hypertrophy. (2) A load-dependent component is more important than a load-independent component in regulating left ventricular NP production. (3) ANF production is more sensitive than BNP production to the load-independent component. (4) Low-dose ramipril treatment reverses hypertrophy and the increased collagen III expression but does not reverse the increased beta-MHC isoform expression, suggesting that these are independently regulated processes. (5) Aortic banding and ACE inhibition do not affect atrial NP production and content.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640983     DOI: 10.1161/01.cir.93.11.2059

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice.

Authors:  B K McConnell; K A Jones; D Fatkin; L H Arroyo; R T Lee; O Aristizabal; D H Turnbull; D Georgakopoulos; D Kass; M Bond; H Niimura; F J Schoen; D Conner; D A Fischman; C E Seidman; J G Seidman; D H Fischman
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Angiotensin II stimulates hyperplasia but not hypertrophy in immature ovine cardiomyocytes.

Authors:  N C Sundgren; G D Giraud; P J S Stork; J G Maylie; K L Thornburg
Journal:  J Physiol       Date:  2003-03-07       Impact factor: 5.182

3.  Influence of acute and chronic myocardial loading conditions, function, structural changes and extracardiac factors on NT-proBNP in asymptomatic patients with preserved ejection fraction.

Authors:  Olaf Schulz; Andre Rudolph; Sarah Scheiner; Helena Mut; Jeanette Schulz-Menger; Gunnar Berghoefer; Ricarda Bensch; Jochen Kraemer; Ingolf Schimke
Journal:  Clin Res Cardiol       Date:  2010-09-02       Impact factor: 5.460

4.  Comparative symptom biochemistry between moderate and advanced heart failure.

Authors:  Christopher S Lee; Quin E Denfeld; Bradley E Aouizerat; Corrine Y Jurgens; Christopher V Chien; Emily Aarons; Jill M Gelow; Shirin O Hiatt; James O Mudd
Journal:  Heart Lung       Date:  2018-10-09       Impact factor: 2.210

5.  Gene expression profiling of dilated cardiomyopathy in older male EP4 knockout mice.

Authors:  Pamela Harding; Xiao-Ping Yang; James Yang; Ed Shesely; Quan He; Margot C LaPointe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-11       Impact factor: 4.733

6.  Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction.

Authors:  Rochus Witthaut; Christian Busch; Peter Fraunberger; Autar Walli; Dietrich Seidel; Günter Pilz; Ralph Stuttmann; Norbert Speichermann; Ljifane Verner; Karl Werdan
Journal:  Intensive Care Med       Date:  2003-08-12       Impact factor: 17.440

7.  Effects of immobilizations stress with or without water immersion on the expression of atrial natriuretic peptide in the hearts of two rat strains.

Authors:  Jana Slavikova; Eliska Mistrova; Vera Klenerova; Peter Kruzliak; Martin Caprnda; Sixtus Hynie; Pavel Sida; Magdalena Chottova Dvorakova
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

8.  Natriuretic peptides in chronic kidney disease.

Authors:  Rajat Tagore; Lieng H Ling; Hong Yang; Hla-Yee Daw; Yiong-Huak Chan; Sunil K Sethi
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-16       Impact factor: 8.237

9.  Association of plasma B-type natriuretic peptide concentrations with longitudinal blood pressure tracking in African Americans: findings from the Jackson Heart Study.

Authors:  Ervin R Fox; Solomon K Musani; Preeti Singh; Aurelian Bidulescu; Harsha S Nagarajarao; Tandaw E Samdarshi; Michael W Steffes; Thomas J Wang; Herman A Taylor; Ramachandran S Vasan
Journal:  Hypertension       Date:  2012-11-26       Impact factor: 10.190

10.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.